Virpax's NES100 to be Presented at The Society of Toxicology by NCATS

Stock Information for Virpax Pharmaceuticals Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Virpax Pharmaceuticals Inc.

Virpax Pharmaceuticals Announces Reverse Stock Split
Virpax Receives Positive Probudur(TM) Results for Dose Range Study Moves Towards Next Steps in IND
Virpax Looking to Use MET to Develop Intranasal COVID Vaccine
Virpax Reports Positive Results in Human Study for its Molecular Envelope Technology
Virpax Confirms Positive Results with US Army with Probudur(TM) for Combat Care Study
Virpax's Matthew Barnes to Present at Outsourcing in Clinical Trials Conference
Spartan Capital Securities Serves as Sole Placement Agent in Virpax Pharmaceuticals' $6 Million Follow-On Offering
Virpax Pharmaceuticals, Inc. Announces Closing of $6.0 Million Public Offering of Common Stock and Pre-Funded Warrants

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.